DXCM News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

DX

Mkt Cap

$32.47B

Volume

2.79M

Next Earnings

October 29th

Loading chart

DX

DXCMDexCom, Inc.

DXCM

Pay with—

Available Balance0.00

DX

Mkt Cap

$33.10B

Volume

2.79M

Next Earnings

October 29th

Chart Financials Earnings News About Insider Filings

Vaso Stock Surges 149% in a Year: What's Behind the Rally?Vaso Corporation (VASO) has gained 149% over the past year, significantly outperforming its industry peers and the S&P 500. The healthcare-focused company reported improved Q2 2026 results with higher revenues and profitability, driven by growth in professional sales services and medical device segments. Following the divestiture of its IT services business, VASO is streamlining operations and strengthening its focus on healthcare. However, the company faces challenges including heavy dependence on GE HealthCare and ongoing profitability pressures in its proprietary medical products division.Zacks Investment Research · Oct 16, 2026

Here's Why You Should Retain DexCom Stock in Your Portfolio for NowDexCom (DXCM) reported strong Q2 2026 results with gross margin expanding to 64.1% and operating margin at 25.1%, driven by manufacturing efficiencies and G7 15-day product transition. However, near-term profitability could face pressure from Ireland factory ramp-up costs, forex headwinds, and higher oil-linked input costs. The company maintains a Zacks Rank #3 (Hold) rating with shares up 29.4% year-to-date.Zacks Investment Research · Oct 13, 2026

DXCM Report Highlights CGM Growth Opportunity in Type 2 Diabetes CareDexcom released its 2026 State of Type 2 Report highlighting significant gaps in CGM awareness and reimbursement access, with 55% of Type 2 diabetes patients having limited knowledge of the technology. However, the report reveals substantial growth opportunities as 58% of Type 2 patients on GLP-1 medicines use CGM, and a majority are open to CGM when recommended alongside GLP-1 therapy. Competitors Abbott Laboratories and MiniMed are also expanding their CGM portfolios with innovative features and sensor technologies.Zacks Investment Research · Oct 2, 2026

ViCentra Presents Large-Scale Real-World Evidence Demonstrating Kaleido Insulin Patch Pump System Delivers Stable Glucose Control with Very Low HypoglycemiaViCentra announced real-world data from 3,918 adults showing its Kaleido insulin patch pump system achieved 72.2% median time in range with minimal hypoglycemia (0.21% time below 54 mg/dL) and low glycemic variability (28.7% coefficient of variation) across Germany, the Netherlands, and France. The system, integrated with Diabeloop's DBLG1 algorithm and Dexcom G6, demonstrated strong clinical performance in routine use with high user engagement.GlobeNewswire Inc. · Oct 1, 2026

Here's Why DexCom (DXCM) is a Strong Growth StockDexCom (DXCM), a medical device company specializing in continuous glucose monitoring systems, receives a #3 (Hold) rating from Zacks with a VGM Score of B. The company shows strong growth prospects with a Growth Style Score of A and forecasted year-over-year earnings growth of 26.3%. Seven analysts have revised earnings estimates upward in the last 60 days, with the consensus estimate increasing to $2.64 per share and an average earnings surprise of +11.4%.Zacks Investment Research · Sep 29, 2026

Here's How Much a $1000 Investment in DexCom Made 10 Years Ago Would Be Worth TodayA $1,000 investment in DexCom (DXCM) made 10 years ago in August 2016 would be worth $3,981.59 as of August 31, 2026, representing a 298.16% gain. This significantly outperformed the S&P 500's 255.54% gain over the same period. DexCom, a medical device company specializing in continuous glucose monitoring systems, reported 2025 revenues of $4.66 billion (up 16% YoY) and adjusted EPS of $2.09 (up 27.4% YoY). Analysts remain optimistic about future growth despite competitive market pressures.Zacks Investment Research · Aug 31, 2026

Global Blood Glucose Monitoring System Market Size to Reach USD 39.4 Billion by 2035 | Growing at 8.9% CAGR | Industry Trends, Market Share & Forecast – Custom Market InsightsThe global blood glucose monitoring system market is valued at USD 16.8 billion in 2025 and is projected to reach USD 39.4 billion by 2035, growing at a CAGR of 8.9%. Growth is driven by AI-enabled monitoring systems, increasing diabetes prevalence, and rising adoption of home healthcare solutions. Key players include Medtronic, Abbott, Dexcom, and Roche, with recent partnerships like Abbott-Medtronic collaboration to integrate continuous glucose monitoring with automated insulin delivery systems.GlobeNewswire Inc. · Jul 14, 2026

3 Stocks Doing the Heavy Lifting in Healthcare’s ReboundThe healthcare sector is rebounding after a lackluster start to 2026, driven by rotation from tech and stabilizing costs. Three stocks are leading the rally: Eli Lilly (up 11% in a month) on strong GLP-1 drug sales and new oral pill approval; Humana (up 18% in a month) as medical utilization moderates and margins widen; and DexCom (up 15% in a month) expanding into non-insulin Type 2 diabetes markets with landmark trial data.Investing.com · Jun 18, 2026

Dexcom Scores Pediatric Expansion For OTC Stelo Glucose MonitorThe FDA cleared Dexcom's Stelo Glucose Biosensor System for over-the-counter use in children ages 2 and older who do not use insulin, marking the first OTC continuous glucose monitor authorized for this pediatric population. The device tracks glucose levels every 15 minutes and each sensor lasts up to 15 days. The clearance was based on clinical studies and real-world evidence. Dexcom shares were down 2.2% at the time of publication.Benzinga · Jun 15, 2026

[Latest] Non-Invasive Blood Glucose Monitoring Devices Market Size to Hit USD 340.49 Million with a Promising CAGR of 25.60% by 2034 - Report by Zion Market Research (ZMR)The global non-invasive blood glucose monitoring devices market is projected to grow from USD 34.86 million in 2024 to USD 340.49 million by 2034, with a CAGR of 25.60%. Growth is driven by rising diabetes prevalence, increasing demand for painless monitoring, and technological advancements in wearables and optical sensing. Spectroscopy technology and homecare segments are expected to lead the market, while North America will dominate regionally.GlobeNewswire Inc. · Jun 4, 2026

to start trading

DX

DXCMDexCom, Inc.

DXCM

Pay with—

Available Balance0.00

Your PositionYou don't own any DXCM yet.

Related Tickers

Earnings